Study Stopped
Early termination was approved due to compelling efficacy of LCZ696 in patients with HF \& reduced EF after final pre-specified interim analysis 28-Mar-2014.
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
PARADIGM-HF
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction
2 other identifiers
interventional
8,442
46 countries
1009
Brief Summary
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =\< 35%).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2009
Typical duration for phase_3
1009 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 16, 2009
CompletedFirst Posted
Study publicly available on registry
December 18, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2014
CompletedResults Posted
Study results publicly available
September 7, 2015
CompletedAugust 15, 2016
July 1, 2016
4.4 years
December 16, 2009
August 6, 2015
July 13, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.
up to 51 months
Secondary Outcomes (5)
Number of Patients - All-cause Mortality
up to 51 months
Number of Patients Reported With Adjudicated Primary Causes of Death
up to 51 months
Change From Baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
Baseline, Month 8
Number of Patients With First Confirmed Renal Dysfunction
up to 51 months
Percentage of Participants With New Onset of Atrial Fibrillation (AF)
up to 51 months
Study Arms (2)
LCZ696
EXPERIMENTALsingle-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
Enalapril
ACTIVE COMPARATORsingle-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
Interventions
Eligibility Criteria
You may qualify if:
- Patients must give written informed consent before any assessment is performed.
- Outpatients ≥ 18 years of age, male or female.
- Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction (EF =\< 35%) and elevated BNP.
- Patients must be on an ACEI or an ARB at a stable dose of at least enalapril 10 mg/d or equivalent for at least 4 weeks.
- Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks.
You may not qualify if:
- Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
- History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drugs.
- Previous history of intolerance to recommended target doses of ACEIs or ARBs
- Known history of angioedema.
- Requirement of treatment with both ACEIs and ARBs.
- Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).
- Symptomatic hypotension and/or a SBP \< 100 mmHg.
- Estimated GFR \< 30 mL/min/1.73m2 as measured by the simplified MDRD formula
- Serum potassium \> 5.2 mmol/L.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1031)
Novartis Investigative Site
Birmingham, Alabama, 35209, United States
Novartis Investigative Site
Birmingham, Alabama, 35211, United States
Novartis Investigative Site
Huntsville, Alabama, 35801, United States
Novartis Investigative Site
Mobile, Alabama, 36608, United States
Novartis Investigative Site
Muscle Shoals, Alabama, 35662, United States
Novartis Investigative Site
Anchorage, Alaska, 99508, United States
Novartis Investigative Site
Gilbert, Arizona, 85234, United States
Novartis Investigative Site
Phoenix, Arizona, 85006, United States
Novartis Investigative Site
Phoenix, Arizona, 85020, United States
Novartis Investigative Site
Little Rock, Arkansas, 72204, United States
Novartis Investigative Site
Little Rock, Arkansas, 72205, United States
Novartis Investigative Site
Anaheim, California, 92801, United States
Novartis Investigative Site
Bellflower, California, 90706, United States
Novartis Investigative Site
Berkley, California, 94705, United States
Novartis Investigative Site
Loma Linda, California, 92357, United States
Novartis Investigative Site
Los Angeles, California, 90033, United States
Novartis Investigative Site
Los Angeles, California, 90073, United States
Novartis Investigative Site
Mather, California, 95655, United States
Novartis Investigative Site
Oceanside, California, 92056, United States
Novartis Investigative Site
Palm Springs, California, 92262, United States
Novartis Investigative Site
Pomona, California, 91767, United States
Novartis Investigative Site
Sacramento, California, 95816, United States
Novartis Investigative Site
San Diego, California, 92103, United States
Novartis Investigative Site
San Diego, California, 92161, United States
Novartis Investigative Site
Santa Rosa, California, 95405, United States
Novartis Investigative Site
Stockton, California, 95204, United States
Novartis Investigative Site
Tustin, California, 92780, United States
Novartis Investigative Site
Denver, Colorado, 80206, United States
Novartis Investigative Site
Denver, Colorado, 80220, United States
Novartis Investigative Site
Stamford, Connecticut, 06905, United States
Novartis Investigative Site
Washington D.C., District of Columbia, 20422, United States
Novartis Investigative Site
Boynton Beach, Florida, 33472-2952, United States
Novartis Investigative Site
Davie, Florida, 33324, United States
Novartis Investigative Site
Fort Lauderdale, Florida, 33316, United States
Novartis Investigative Site
Gainesville, Florida, 32608, United States
Novartis Investigative Site
Jacksonville, Florida, 32209-6511, United States
Novartis Investigative Site
Jacksonville, Florida, 32216, United States
Novartis Investigative Site
Jacksonville, Florida, 32223, United States
Novartis Investigative Site
Lakeland, Florida, 33805, United States
Novartis Investigative Site
Leesburg, Florida, 34748, United States
Novartis Investigative Site
Port Charlotte, Florida, 33952, United States
Novartis Investigative Site
Tamarac, Florida, 33321, United States
Novartis Investigative Site
Tampa, Florida, 33609, United States
Novartis Investigative Site
Covington, Georgia, 30014, United States
Novartis Investigative Site
Decatur, Georgia, 30030, United States
Novartis Investigative Site
Honolulu, Hawaii, 96813, United States
Novartis Investigative Site
Honolulu, Hawaii, 96817, United States
Novartis Investigative Site
Chicago, Illinois, 60612, United States
Novartis Investigative Site
Maywood, Illinois, 60153, United States
Novartis Investigative Site
Melrose Park, Illinois, 60160, United States
Novartis Investigative Site
Park Ridge, Illinois, 60068, United States
Novartis Investigative Site
Quincy, Illinois, 62301, United States
Novartis Investigative Site
Des Moines, Iowa, 50314, United States
Novartis Investigative Site
Pratt, Kansas, 67124, United States
Novartis Investigative Site
Topeka, Kansas, 66606, United States
Novartis Investigative Site
Wichita, Kansas, 67207, United States
Novartis Investigative Site
Alexandria, Louisiana, 71301, United States
Novartis Investigative Site
Covington, Louisiana, 70433, United States
Novartis Investigative Site
Lafayette, Louisiana, 70501, United States
Novartis Investigative Site
Slidell, Louisiana, 70458, United States
Novartis Investigative Site
Biddeford, Maine, 04005, United States
Novartis Investigative Site
South Portland, Maine, 04106, United States
Novartis Investigative Site
Baltimore, Maryland, 21208, United States
Novartis Investigative Site
Beltsville, Maryland, 20705, United States
Novartis Investigative Site
Columbia, Maryland, 21044, United States
Novartis Investigative Site
Nottingham, Maryland, 21236, United States
Novartis Investigative Site
Ayer, Massachusetts, 01432, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Haverhill, Massachusetts, 01830, United States
Novartis Investigative Site
Natick, Massachusetts, 01760, United States
Novartis Investigative Site
Ann Arbor, Michigan, 48106, United States
Novartis Investigative Site
Detroit, Michigan, 48202, United States
Novartis Investigative Site
Lapeer, Michigan, 48446, United States
Novartis Investigative Site
Saginaw, Michigan, 48601, United States
Novartis Investigative Site
Minneapolis, Minnesota, 55417, United States
Novartis Investigative Site
Saint Paul, Minnesota, 55102, United States
Novartis Investigative Site
Picayune, Mississippi, 39466, United States
Novartis Investigative Site
Rolling Fork, Mississippi, 39159, United States
Novartis Investigative Site
Springfield, Missouri, 65804, United States
Novartis Investigative Site
Springfield, Missouri, 65807, United States
Novartis Investigative Site
Fremont, Nebraska, 68025, United States
Novartis Investigative Site
Grand Island, Nebraska, 68803, United States
Novartis Investigative Site
Omaha, Nebraska, 68131, United States
Novartis Investigative Site
Nashua, New Hampshire, 03060, United States
Novartis Investigative Site
Elizabeth, New Jersey, 07202, United States
Novartis Investigative Site
Hamilton, New Jersey, 08690, United States
Novartis Investigative Site
New Brunswick, New Jersey, 08901, United States
Novartis Investigative Site
Newark, New Jersey, 07103-2714, United States
Novartis Investigative Site
Ocean City, New Jersey, 07712, United States
Novartis Investigative Site
Albuquerque, New Mexico, 87102, United States
Novartis Investigative Site
Cordtlandt Manor, New York, 10567, United States
Novartis Investigative Site
Laurelton, New York, 11422, United States
Novartis Investigative Site
New York, New York, 10032, United States
Novartis Investigative Site
Northport, New York, 11768, United States
Novartis Investigative Site
Asheboro, North Carolina, 27204, United States
Novartis Investigative Site
Asheville, North Carolina, 28803, United States
Novartis Investigative Site
Cary, North Carolina, 27511, United States
Novartis Investigative Site
Greensboro, North Carolina, 27401, United States
Novartis Investigative Site
Raleigh, North Carolina, 27610, United States
Novartis Investigative Site
Wilmington, North Carolina, 28401, United States
Novartis Investigative Site
Cadiz, Ohio, 43907, United States
Novartis Investigative Site
Canton, Ohio, 44710, United States
Novartis Investigative Site
Cincinnati, Ohio, 45219, United States
Novartis Investigative Site
Cincinnati, Ohio, 45267-0585, United States
Novartis Investigative Site
Cleveland, Ohio, 44195, United States
Novartis Investigative Site
Columbus, Ohio, 43210, United States
Novartis Investigative Site
Marion, Ohio, 43302, United States
Novartis Investigative Site
Bartlesville, Oklahoma, 74006, United States
Novartis Investigative Site
Oklahoma City, Oklahoma, 73104, United States
Novartis Investigative Site
Oklahoma City, Oklahoma, 73120, United States
Novartis Investigative Site
Stillwater, Oklahoma, 74074, United States
Novartis Investigative Site
Tulsa, Oklahoma, 74104-4243, United States
Novartis Investigative Site
Tulsa, Oklahoma, 74136, United States
Novartis Investigative Site
Portland, Oregon, 97239-3098, United States
Novartis Investigative Site
Aliquippa, Pennsylvania, 15001, United States
Novartis Investigative Site
Beaver, Pennsylvania, 15009, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, 19102-1192, United States
Novartis Investigative Site
Pittsburgh, Pennsylvania, 15206, United States
Novartis Investigative Site
Charleston, South Carolina, 29401-5799, United States
Novartis Investigative Site
Rapid City, South Dakota, 57701, United States
Novartis Investigative Site
Memphis, Tennessee, 38104, United States
Novartis Investigative Site
Nashville, Tennessee, 37203, United States
Novartis Investigative Site
Nashville, Tennessee, 37212, United States
Novartis Investigative Site
Amarillo, Texas, 79106, United States
Novartis Investigative Site
Arlington, Texas, 76012, United States
Novartis Investigative Site
Beaumont, Texas, 77701, United States
Novartis Investigative Site
Beaumont, Texas, 77702, United States
Novartis Investigative Site
Brownsville, Texas, 78520, United States
Novartis Investigative Site
Dallas, Texas, 75231, United States
Novartis Investigative Site
Dallas, Texas, 75235, United States
Novartis Investigative Site
Dallas, Texas, 75251, United States
Novartis Investigative Site
Dallas, Texas, 75390, United States
Novartis Investigative Site
Grapevine, Texas, 76051, United States
Novartis Investigative Site
Houston, Texas, 77024, United States
Novartis Investigative Site
Houston, Texas, 77025, United States
Novartis Investigative Site
Houston, Texas, 77030, United States
Novartis Investigative Site
Houston, Texas, 77070, United States
Novartis Investigative Site
Houston, Texas, 77081, United States
Novartis Investigative Site
Kingwood, Texas, 77339, United States
Novartis Investigative Site
Livingston, Texas, 77351, United States
Novartis Investigative Site
Lufkin, Texas, 75904, United States
Novartis Investigative Site
Odessa, Texas, 79761, United States
Novartis Investigative Site
Plano, Texas, 75024, United States
Novartis Investigative Site
Tyler, Texas, 75701, United States
Novartis Investigative Site
Layton, Utah, 84041, United States
Novartis Investigative Site
Fredericksburg, Virginia, 22401, United States
Novartis Investigative Site
Richmond, Virginia, 23219, United States
Novartis Investigative Site
Richmond, Virginia, 23249, United States
Novartis Investigative Site
Seattle, Washington, 98103, United States
Novartis Investigative Site
Spokane, Washington, 99204, United States
Novartis Investigative Site
Tacoma, Washington, 98405, United States
Novartis Investigative Site
Madison, Wisconsin, 53792-1615, United States
Novartis Investigative Site
Milwaukee, Wisconsin, 53295, United States
Novartis Investigative Site
Waukesha, Wisconsin, 53188, United States
Novartis Investigative Site
Wausau, Wisconsin, 54401, United States
Novartis Investigative Site
Buenos Aires, Buenos Aires, C1090AAH, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, C1209ABD, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, C1405BCH, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, C1426EGR, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, C1221ADC, Argentina
Novartis Investigative Site
Caba, Buenos Aires, C1425DTG, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, C1119ACN, Argentina
Novartis Investigative Site
Lanús, Buenos Aires, B1824ABE, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, B7600DHK, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, B7600FZD, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, B7600FZN, Argentina
Novartis Investigative Site
Munro, Buenos Aires, B1605DSX, Argentina
Novartis Investigative Site
Pilar, Buenos Aires, B1629AHJ, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, B1878DVB, Argentina
Novartis Investigative Site
San Isidro, Buenos Aires, B1642DJG, Argentina
Novartis Investigative Site
Zárate, Buenos Aires, 2800, Argentina
Novartis Investigative Site
Caba, Buenos Aires F.D., C1179AAB, Argentina
Novartis Investigative Site
Caba, Buenos Aires F.D., C1425FVH, Argentina
Novartis Investigative Site
Trelew, Chubut Province, U9100AQR, Argentina
Novartis Investigative Site
Corrientes, Corrientes Province, W3400CLH, Argentina
Novartis Investigative Site
Corrientes, Corrientes Province, W3400, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, 5000, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5000AAW, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5000AAX, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5000BSQ, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5003DCP, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5006IKK, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5009BSN, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5014OPO, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5016KEH, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, X5016KET, Argentina
Novartis Investigative Site
Formosa, Formosa Province, P3600, Argentina
Novartis Investigative Site
Formosa, Formosa Province, P3634XAR, Argentina
Novartis Investigative Site
San Salvador de Jujuy, Jujuy Province, Y4600ABF, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, M5500AAJ, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, M5500CHC, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, M5500EOB, Argentina
Novartis Investigative Site
Cipolletti, Río Negro Province, 8324, Argentina
Novartis Investigative Site
Salta, Salta Province, A4400ANG, Argentina
Novartis Investigative Site
Buenos Aires, San Juan Province, Argentina
Novartis Investigative Site
San Juan, San Juan Province, J5402DIL, Argentina
Novartis Investigative Site
San Luis, San Luis Province, D5702JRS, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, 2000, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, S2000AII, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, S2001SBL, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, S2002KDS, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, S200CXP, Argentina
Novartis Investigative Site
Santa Fe, Santa Fe Province, S3000EOZ, Argentina
Novartis Investigative Site
Santa Fe, Santa Fe Province, S3000FWO, Argentina
Novartis Investigative Site
Santiago del Estero, Santiago del Estero Province, G4200AQK, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, T4000EBR, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, T4000IIH, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, T4000JCU, Argentina
Novartis Investigative Site
Heusden-Zolder, Belgium, 3550, Belgium
Novartis Investigative Site
Antwerp, 2060, Belgium
Novartis Investigative Site
Baudour, 7331, Belgium
Novartis Investigative Site
Bonheiden, 2820, Belgium
Novartis Investigative Site
Brasschaat, 2930, Belgium
Novartis Investigative Site
Bruges, 8000, Belgium
Novartis Investigative Site
Brussels, 1070, Belgium
Novartis Investigative Site
Brussels, 1090, Belgium
Novartis Investigative Site
Ghent, 9000, Belgium
Novartis Investigative Site
Hasselt, 3500, Belgium
Novartis Investigative Site
La Louvière, 7100, Belgium
Novartis Investigative Site
Leuven, 3000, Belgium
Novartis Investigative Site
Ottignies, 1340, Belgium
Novartis Investigative Site
Ronse, 9600, Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, 40140-110, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, 41810-010, Brazil
Novartis Investigative Site
Brasília, Federal District, 70390-903, Brazil
Novartis Investigative Site
Goiânia, Goiás, 74223-130, Brazil
Novartis Investigative Site
Goiânia, Goiás, 74605-050, Brazil
Novartis Investigative Site
Goiânia, Goiás, 74823-470, Brazil
Novartis Investigative Site
São Luís, Maranhão, 65020-070, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 20180-090, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 30150-221, Brazil
Novartis Investigative Site
Uberlândia, Minas Gerais, 38400-368, Brazil
Novartis Investigative Site
Curitiba, Paraná, 80730-150, Brazil
Novartis Investigative Site
Belém, Pará, 66087-660, Brazil
Novartis Investigative Site
Recife, Pernambuco, 50100-030, Brazil
Novartis Investigative Site
Recife, Pernambuco, 50100-130, Brazil
Novartis Investigative Site
Recife, Pernambuco, 52051 - 38, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, 21941-590, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, 22261-010, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, 22280-020, Brazil
Novartis Investigative Site
Natal, Rio Grande do Norte, 59020-035, Brazil
Novartis Investigative Site
Passo Fundo, Rio Grande do Sul, 99010-080, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90620-001, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 92425900, Brazil
Novartis Investigative Site
Marília, São Paulo, 17515-000, Brazil
Novartis Investigative Site
Ribeirão Preto, São Paulo, 14055-370, Brazil
Novartis Investigative Site
Santo André, São Paulo, 09030-640, Brazil
Novartis Investigative Site
Santo André, São Paulo, 09190-615, Brazil
Novartis Investigative Site
São José do Rio Preto, São Paulo, 15015-750, Brazil
Novartis Investigative Site
São Paulo, São Paulo, 01327-010, Brazil
Novartis Investigative Site
São Paulo, São Paulo, 01506-000, Brazil
Novartis Investigative Site
São Paulo, São Paulo, 05403-000, Brazil
Novartis Investigative Site
Votuporanga, São Paulo, 15500-003, Brazil
Novartis Investigative Site
Burgas, Bulgaria, 8000, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria, 4000, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria, 4004, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, 1309, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, 1431, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, 1505, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, 1527, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria, 1606, Bulgaria
Novartis Investigative Site
Haskovo, 6300, Bulgaria
Novartis Investigative Site
Pazardzhik, 4400, Bulgaria
Novartis Investigative Site
Pleven, 5800, Bulgaria
Novartis Investigative Site
Plovdiv, 4002, Bulgaria
Novartis Investigative Site
Rousse, 7002, Bulgaria
Novartis Investigative Site
Shumen, 9700, Bulgaria
Novartis Investigative Site
Silistra, 7500, Bulgaria
Novartis Investigative Site
Sofia, 1202, Bulgaria
Novartis Investigative Site
Sofia, 1233, Bulgaria
Novartis Investigative Site
Sofia, 1431, Bulgaria
Novartis Investigative Site
Sofia, 1606, Bulgaria
Novartis Investigative Site
Stara Zagora, 6000, Bulgaria
Novartis Investigative Site
Varna, 9010, Bulgaria
Novartis Investigative Site
Veliko Tarnovo, 5000, Bulgaria
Novartis Investigative Site
New Westminster, British Columbia, V3L 3W4, Canada
Novartis Investigative Site
Surrey, British Columbia, V3V 1N1, Canada
Novartis Investigative Site
Victoria, British Columbia, V8R4R2, Canada
Novartis Investigative Site
Moncton, New Brunswick, E1G 1A7, Canada
Novartis Investigative Site
Halifax, Nova Scotia, B3H 2Y9, Canada
Novartis Investigative Site
Cambridge, Ontario, N1R 6V6, Canada
Novartis Investigative Site
Greater Sudbury, Ontario, P3E 3B8, Canada
Novartis Investigative Site
Kitchener, Ontario, N2M 5N4, Canada
Novartis Investigative Site
London, Ontario, N6A 5A5, Canada
Novartis Investigative Site
Oshawa, Ontario, L1J 2K1, Canada
Novartis Investigative Site
Toronto, Ontario, M5B 1W8, Canada
Novartis Investigative Site
Toronto, Ontario, M5G 1X5, Canada
Novartis Investigative Site
Toronto, Ontario, M5G 2N2, Canada
Novartis Investigative Site
Weston, Ontario, M9N 1W4, Canada
Novartis Investigative Site
Granby, Quebec, J2G 1T7, Canada
Novartis Investigative Site
Lachine, Quebec, H8S 2E4, Canada
Novartis Investigative Site
Laval, Quebec, H7M 3L9, Canada
Novartis Investigative Site
Lévis, Quebec, G6V 4Z5, Canada
Novartis Investigative Site
Longueuil, Quebec, J4M 2X1, Canada
Novartis Investigative Site
Montreal, Quebec, H2W 1T8, Canada
Novartis Investigative Site
Montreal, Quebec, H3A 1A1, Canada
Novartis Investigative Site
Montreal, Quebec, H3G 1A4, Canada
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site
Sainte-Foy, Quebec, G1V 4G5, Canada
Novartis Investigative Site
Sherbrooke, Quebec, J1G-2E8, Canada
Novartis Investigative Site
St-Georges Beauce, Quebec, G5Y 4T8, Canada
Novartis Investigative Site
Thetford-Mines, Quebec, G6G 2V4, Canada
Novartis Investigative Site
Regina, Saskatchewan, S4P 0w5, Canada
Novartis Investigative Site
Los Ángeles, Bio Bio, 4440000, Chile
Novartis Investigative Site
Temuco, Cautin, Chile
Novartis Investigative Site
Temuco, Región de la Araucanía, 4780000, Chile
Novartis Investigative Site
San Miguel, Santiago Metropolitan, 8900000, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, 8360160, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Vitacura, Santiago Metropolitan, 7630000, Chile
Novartis Investigative Site
Talcahuano, Chile
Novartis Investigative Site
Beijing, Beijing Municipality, 100037, China
Novartis Investigative Site
Harbin, Heilongjiang, 150001, China
Novartis Investigative Site
Changsha, Hunan, 410003, China
Novartis Investigative Site
Nanjing, Jiangsu, 210009, China
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Shenyang, Liaoning, 110003, China
Novartis Investigative Site
Xi’an, Shanxi, 710061, China
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
Novartis Investigative Site
Hangzhou, Zhejiang, 310009, China
Novartis Investigative Site
Baotou, 014040, China
Novartis Investigative Site
Beijing, 100029, China
Novartis Investigative Site
Beijing, 100044, China
Novartis Investigative Site
Beijing, 100730, China
Novartis Investigative Site
Chongqing, 400037, China
Novartis Investigative Site
Shanghai, 200080, China
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Barranquilla, Colombia, Colombia
Novartis Investigative Site
Cali, Colombia, Colombia
Novartis Investigative Site
Cartegena, Colombia, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, 0000, Colombia
Novartis Investigative Site
Cartagena, Departamento de Bolívar, Colombia
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia
Novartis Investigative Site
Floridablanca, Santander Department, 57-7, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Florida Blanca, Colombia
Novartis Investigative Site
Medellín, Colombia
Novartis Investigative Site
Beroun, Czech Republic, 266 01, Czechia
Novartis Investigative Site
Brandýs nad Labem, Czech Republic, 250 01, Czechia
Novartis Investigative Site
Hořovice, Czech Republic, 268 01, Czechia
Novartis Investigative Site
Jablonec nad Nisou, Czech Republic, 466 01, Czechia
Novartis Investigative Site
Karlovy Vary, Czech Republic, 360 09, Czechia
Novartis Investigative Site
Kladno, Czech Republic, 272 80, Czechia
Novartis Investigative Site
Klatovy, Czech Republic, 339 01, Czechia
Novartis Investigative Site
Liberec V Kristianova, Czech Republic, 460 05, Czechia
Novartis Investigative Site
Mělník, Czech Republic, 276 01, Czechia
Novartis Investigative Site
Olomouc, Czech Republic, 779 00, Czechia
Novartis Investigative Site
Pilsen, Czech Republic, 301 00, Czechia
Novartis Investigative Site
Prague, Czech Republic, 142 00, Czechia
Novartis Investigative Site
Prague 10, Vrsovice, Czech Republic, 10100, Czechia
Novartis Investigative Site
Semily, Czech Republic, 513 31, Czechia
Novartis Investigative Site
Strakonice, Czech Republic, 38601, Czechia
Novartis Investigative Site
Třebíč, Czech Republic, 674 01, Czechia
Novartis Investigative Site
Ústí nad Labem, Czech Republic, 400 01, Czechia
Novartis Investigative Site
Bílovec, CZE, 743 01, Czechia
Novartis Investigative Site
Prague, CZE, 128 08, Czechia
Novartis Investigative Site
Kolín, 280 20, Czechia
Novartis Investigative Site
Prague, 110 00, Czechia
Novartis Investigative Site
Prague, 128 08, Czechia
Novartis Investigative Site
Prague, 150 30, Czechia
Novartis Investigative Site
Uherské Hradiště, 686 01, Czechia
Novartis Investigative Site
Uherské Hradiště, 68601, Czechia
Novartis Investigative Site
Hellerup, Denmark, DK-2900, Denmark
Novartis Investigative Site
Aarhus C, DK-8000, Denmark
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
Novartis Investigative Site
Esbjerg, DK-6700, Denmark
Novartis Investigative Site
Herning, DK-7400, Denmark
Novartis Investigative Site
Randers NØ, DK-8930, Denmark
Novartis Investigative Site
Roskilde, DK-4000, Denmark
Novartis Investigative Site
Svendborg, DK-5700, Denmark
Novartis Investigative Site
Vejle, DK-7100, Denmark
Novartis Investigative Site
Viborg, DK-8800, Denmark
Novartis Investigative Site
Santo Domingo, Republica Dominicana, Dominican Republic
Novartis Investigative Site
Santo Domingo, Santo Domingo Province, Dominican Republic
Novartis Investigative Site
Guayaquil, Guayas, 412, Ecuador
Novartis Investigative Site
Guayaquil, Guayas, 559, Ecuador
Novartis Investigative Site
Guayaquil, Guayas, Ecuador
Novartis Investigative Site
Quito, Pichincha, 1701, Ecuador
Novartis Investigative Site
Tallinn, Estonia, 10138, Estonia
Novartis Investigative Site
Haabneeme, Viimsi Vald, 74001, Estonia
Novartis Investigative Site
Tallinn, 13419, Estonia
Novartis Investigative Site
Tartu, 50410, Estonia
Novartis Investigative Site
Kuopio, Finland, 70100, Finland
Novartis Investigative Site
HUS, 00029, Finland
Novartis Investigative Site
Kemi, FIN-94100, Finland
Novartis Investigative Site
Oulu, 90100, Finland
Novartis Investigative Site
Tampere, 33521, Finland
Novartis Investigative Site
Strasbourg, Cedex, 67091, France
Novartis Investigative Site
Abbeville, 80100, France
Novartis Investigative Site
Bayonne, 64100, France
Novartis Investigative Site
Bayonne, 64109, France
Novartis Investigative Site
Béziers, 34525, France
Novartis Investigative Site
Bordeaux, 33075, France
Novartis Investigative Site
Caen, 14000, France
Novartis Investigative Site
Cholet, 49325, France
Novartis Investigative Site
Créteil, 94010, France
Novartis Investigative Site
Essey-lès-Nancy, 54270, France
Novartis Investigative Site
Grenoble, 38043, France
Novartis Investigative Site
Lagny-sur-Marne, 77405, France
Novartis Investigative Site
Langres, 52206, France
Novartis Investigative Site
Le Chesnay, France
Novartis Investigative Site
Le Plessis-Robinson, 92350, France
Novartis Investigative Site
Limoges, 87001, France
Novartis Investigative Site
Lomme, 59462, France
Novartis Investigative Site
Montpellier, 34195, France
Novartis Investigative Site
Nice, 06602, France
Novartis Investigative Site
Paris, 75010, France
Novartis Investigative Site
Paris, 75015, France
Novartis Investigative Site
Reims, 51092, France
Novartis Investigative Site
Rouen, 76031, France
Novartis Investigative Site
Saint-Aubin-lès-Elbeuf, 76410, France
Novartis Investigative Site
Toulouse, 31059, France
Novartis Investigative Site
Tourcoing, 59208, France
Novartis Investigative Site
Valencienne, 59322, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site
Berlin, Germany, 10117, Germany
Novartis Investigative Site
Ludwigshafen, Germany, 67061, Germany
Novartis Investigative Site
Ahrensfelde, 16356, Germany
Novartis Investigative Site
Bad Homburg, 61348, Germany
Novartis Investigative Site
Bad Krozingen, 79189, Germany
Novartis Investigative Site
Bad Salzuflen, 32105, Germany
Novartis Investigative Site
Bad Schwartau, 23611, Germany
Novartis Investigative Site
Barsinghausen, 30890, Germany
Novartis Investigative Site
Berlin, 10115, Germany
Novartis Investigative Site
Berlin, 10369, Germany
Novartis Investigative Site
Berlin, 10559, Germany
Novartis Investigative Site
Berlin, 10787, Germany
Novartis Investigative Site
Berlin, 10789, Germany
Novartis Investigative Site
Berlin, 13055, Germany
Novartis Investigative Site
Berlin, 13347, Germany
Novartis Investigative Site
Berlin, 13509, Germany
Novartis Investigative Site
Berlin, 14050, Germany
Novartis Investigative Site
Bernau, 16321, Germany
Novartis Investigative Site
Bitburg, 54634, Germany
Novartis Investigative Site
Bremen, 28277, Germany
Novartis Investigative Site
Buch, 13125, Germany
Novartis Investigative Site
Chemnitz, 09130, Germany
Novartis Investigative Site
Darmstadt, 64287, Germany
Novartis Investigative Site
Dessau, 06846, Germany
Novartis Investigative Site
Dietzenbach, 63128, Germany
Novartis Investigative Site
Dortmund, 44137, Germany
Novartis Investigative Site
Dresden, 01099, Germany
Novartis Investigative Site
Dresden, 01127, Germany
Novartis Investigative Site
Dresden, 01129, Germany
Novartis Investigative Site
Dresden, 01309, Germany
Novartis Investigative Site
Eilenburg, 04838, Germany
Novartis Investigative Site
Elsterwerda, 04910, Germany
Novartis Investigative Site
Erfurt, 99084, Germany
Novartis Investigative Site
Frankfurt, 60488, Germany
Novartis Investigative Site
Frankfurt, 65929, Germany
Novartis Investigative Site
Georgsmarienhütte, 49124, Germany
Novartis Investigative Site
Giengen an der Brenz, 89537, Germany
Novartis Investigative Site
Goch, 47574, Germany
Novartis Investigative Site
Graben-Neudorf, 76676, Germany
Novartis Investigative Site
Hamburg, 21075, Germany
Novartis Investigative Site
Hamburg, 22041, Germany
Novartis Investigative Site
Hamburg, 22291, Germany
Novartis Investigative Site
Hamburg, 22527, Germany
Novartis Investigative Site
Hamburg, 22765, Germany
Novartis Investigative Site
Hamminkeln, 46499, Germany
Novartis Investigative Site
Hanover, 30165, Germany
Novartis Investigative Site
Heidelberg, 69115, Germany
Novartis Investigative Site
Homburg, 66421, Germany
Novartis Investigative Site
Hoppegarten-Dahlwitz, 15366, Germany
Novartis Investigative Site
Huy / OT Anderbeck, 38836, Germany
Novartis Investigative Site
Ingelheim, 55218, Germany
Novartis Investigative Site
Jena, 07740, Germany
Novartis Investigative Site
Jena, 07743, Germany
Novartis Investigative Site
Kallstadt, 67169, Germany
Novartis Investigative Site
Kassel, 34121, Germany
Novartis Investigative Site
Kassel, 34125, Germany
Novartis Investigative Site
Kassel, 34127, Germany
Novartis Investigative Site
Kelkheim, 65779, Germany
Novartis Investigative Site
Köthen, 06366, Germany
Novartis Investigative Site
Künzelsau, 74653, Germany
Novartis Investigative Site
Langen, 63225, Germany
Novartis Investigative Site
Leipzig, 04103, Germany
Novartis Investigative Site
Leipzig, 04109, Germany
Novartis Investigative Site
Leipzig, 04129, Germany
Novartis Investigative Site
Leipzig, 04315, Germany
Novartis Investigative Site
Leipzig, 04357, Germany
Novartis Investigative Site
Löhne, 32584, Germany
Novartis Investigative Site
Ludwigshafen, 67067, Germany
Novartis Investigative Site
Lübeck, 23558, Germany
Novartis Investigative Site
Lütjenburg, 24321, Germany
Novartis Investigative Site
Mainz, 55116, Germany
Novartis Investigative Site
Mainz, 55131, Germany
Novartis Investigative Site
Mannheim, 68165, Germany
Novartis Investigative Site
Meissen, 01662, Germany
Novartis Investigative Site
Meißen, 01662, Germany
Novartis Investigative Site
Mönchengladbach, 41063, Germany
Novartis Investigative Site
Mühldorf, 84453, Germany
Novartis Investigative Site
Mühlheim, 45468, Germany
Novartis Investigative Site
München, 80336, Germany
Novartis Investigative Site
Münster, 48149, Germany
Novartis Investigative Site
Neunkirchen, 57290, Germany
Novartis Investigative Site
Neunkirchen, 66539, Germany
Novartis Investigative Site
Nienburg, 31582, Germany
Novartis Investigative Site
Offenbach, 63073, Germany
Novartis Investigative Site
Oldenburg i.H., 23758, Germany
Novartis Investigative Site
Osnabrück, 49080, Germany
Novartis Investigative Site
Papenburg, 26871, Germany
Novartis Investigative Site
Rhaunen, 55624, Germany
Novartis Investigative Site
Riesa, 01589, Germany
Novartis Investigative Site
Rodgau, 63110, Germany
Novartis Investigative Site
Saint Ingbert - Oberwuerzbach, 66386, Germany
Novartis Investigative Site
Schenklengsfeld, 36277, Germany
Novartis Investigative Site
Schkeuditz, 04435, Germany
Novartis Investigative Site
Schwäbisch Hall, 74523, Germany
Novartis Investigative Site
Unterschneidheim, 73485, Germany
Novartis Investigative Site
Wangen, 88239, Germany
Novartis Investigative Site
Wardenburg, 26203, Germany
Novartis Investigative Site
Weeze, 47652, Germany
Novartis Investigative Site
Wermsdorf, 04779, Germany
Novartis Investigative Site
Westhofen, 67593, Germany
Novartis Investigative Site
Wetzlar-Naunheim, 35584, Germany
Novartis Investigative Site
Weyhe, 28844, Germany
Novartis Investigative Site
Wolmirstedt, 39326, Germany
Novartis Investigative Site
Guatemala City, Departamento de Guatemala, 01010, Guatemala
Novartis Investigative Site
Guatemala City, Departamento de Guatemala, 01011, Guatemala
Novartis Investigative Site
Guatemala City, Departamento de Guatemala, 01015, Guatemala
Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Hong Kong SAR, Hong Kong
Novartis Investigative Site
Pécs, Baranya, 7621, Hungary
Novartis Investigative Site
Budapest, Hungary, 1122, Hungary
Novartis Investigative Site
Budapest, Hungary, 1134, Hungary
Novartis Investigative Site
Cegléd, Hungary, 2700, Hungary
Novartis Investigative Site
Miskolc, Hungary, 3526, Hungary
Novartis Investigative Site
Baja, 6500, Hungary
Novartis Investigative Site
Balatonfüred, H-8231, Hungary
Novartis Investigative Site
Budapest, 1021, Hungary
Novartis Investigative Site
Budapest, 1027, Hungary
Novartis Investigative Site
Budapest, 1043, Hungary
Novartis Investigative Site
Budapest, 1085, Hungary
Novartis Investigative Site
Budapest, 1096, Hungary
Novartis Investigative Site
Budapest, 1125, Hungary
Novartis Investigative Site
Budapest, 1134, Hungary
Novartis Investigative Site
Budapest, 1145, Hungary
Novartis Investigative Site
Budapest, H-1032, Hungary
Novartis Investigative Site
Budapest, H-1096, Hungary
Novartis Investigative Site
Budapest, H-1106, Hungary
Novartis Investigative Site
Debrecen, 4032, Hungary
Novartis Investigative Site
Eger, H-3300, Hungary
Novartis Investigative Site
Hódmezővásárhely, 6800, Hungary
Novartis Investigative Site
Kaposvár, 7400, Hungary
Novartis Investigative Site
Nagykanizsa, 8800, Hungary
Novartis Investigative Site
Nyiregyháza, 4400, Hungary
Novartis Investigative Site
Pécs, 7643, Hungary
Novartis Investigative Site
Sopron, 9400, Hungary
Novartis Investigative Site
Szeged, H-6720, Hungary
Novartis Investigative Site
Szekszárd, 7100, Hungary
Novartis Investigative Site
Székesfehérvár, 8000, Hungary
Novartis Investigative Site
Zalaegerszeg, 8900, Hungary
Novartis Investigative Site
Kopavogur, 201, Iceland
Novartis Investigative Site
Reykjavik, IS-101, Iceland
Novartis Investigative Site
Reykjavik, IS-109, Iceland
Novartis Investigative Site
Guntur, Andhra Pradesh, 522001, India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500012, India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500082, India
Novartis Investigative Site
Tirupati, Andhra Pradesh, 517501, India
Novartis Investigative Site
Visakhapatnam, Andhra Pradesh, 530 013, India
Novartis Investigative Site
Visakhapatnam, Andhra Pradesh, 530002, India
Novartis Investigative Site
Hyderabad, Andhra Pradesh, India, 500034, India
Novartis Investigative Site
Ahmedabad, Gujarat, 380 013, India
Novartis Investigative Site
Ahmedabad, Gujarat, 380014, India
Novartis Investigative Site
Ahmedabad, Gujarat, 380025, India
Novartis Investigative Site
Anand, Gujarat, 388325, India
Novartis Investigative Site
Rajkot, Gujarat, 360001, India
Novartis Investigative Site
Surat, Gujarat, 395001, India
Novartis Investigative Site
Vadodara, Gujarat, 390015, India
Novartis Investigative Site
Gurgaon, Haryana, 122001, India
Novartis Investigative Site
Indore, India, 452014, India
Novartis Investigative Site
Bangalore, Karnataka, 560038, India
Novartis Investigative Site
Bangalore, Karnataka, 560092, India
Novartis Investigative Site
Banglaore, Karnataka, 560054, India
Novartis Investigative Site
Mangalore, Karnataka, 575002, India
Novartis Investigative Site
Mysore, Karnataka, 570004, India
Novartis Investigative Site
Kochi, Kerala, 683572, India
Novartis Investigative Site
Trivandrum, Kerala, 695011, India
Novartis Investigative Site
Trivandrum, Kerala, 695607, India
Novartis Investigative Site
Mumbai, Maharashtra, 400012, India
Novartis Investigative Site
Nagpur, Maharashtra, 400012, India
Novartis Investigative Site
Nagpur, Maharashtra, 440 010, India
Novartis Investigative Site
Nagpur, Maharashtra, 44000033, India
Novartis Investigative Site
Nashik, Maharashtra, 422 005, India
Novartis Investigative Site
Nashik, Maharashtra, 422002, India
Novartis Investigative Site
Nashik, Maharashtra, 422005, India
Novartis Investigative Site
Pune, Maharashtra, 411 005, India
Novartis Investigative Site
Pune, Maharashtra, 411 011, India
Novartis Investigative Site
Pune, Maharashtra, 411011, India
Novartis Investigative Site
Delhi, National Capital Territory of Delhi, 110080, India
Novartis Investigative Site
Ludhiana, Punjab, 141002, India
Novartis Investigative Site
Bikaner, Rajasthan, 334003, India
Novartis Investigative Site
Jaipur, Rajasthan, 302016, India
Novartis Investigative Site
Kota, Rajasthan, 324005, India
Novartis Investigative Site
Chennai, Tamil Nadu, 600004, India
Novartis Investigative Site
Chennai, Tamil Nadu, 600020, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226003, India
Novartis Investigative Site
Varanasi, Uttar Pradesh, 221 005, India
Novartis Investigative Site
Ahmedabad, 380052, India
Novartis Investigative Site
Hyderabad, 500 063, India
Novartis Investigative Site
Safed, Israel, 13100, Israel
Novartis Investigative Site
Ashkelon, 78278, Israel
Novartis Investigative Site
Hadera, 38100, Israel
Novartis Investigative Site
Haifa, 31096, Israel
Novartis Investigative Site
Haifa, 3436212, Israel
Novartis Investigative Site
Jerusalem, 91031, Israel
Novartis Investigative Site
Jerusalem, 9112001, Israel
Novartis Investigative Site
Petah Tikva, 49100, Israel
Novartis Investigative Site
Rehovot, 76100, Israel
Novartis Investigative Site
Aosta, AO, 11100, Italy
Novartis Investigative Site
Cortona, AR, 52044, Italy
Novartis Investigative Site
Bergamo, BG, 24128, Italy
Novartis Investigative Site
Seriate, BG, 24068, Italy
Novartis Investigative Site
Treviglio, BG, 24047, Italy
Novartis Investigative Site
San Pietro Vernotico, BR, 72027, Italy
Novartis Investigative Site
Bolzano, BZ, 39100, Italy
Novartis Investigative Site
Cosenza, CS, 87100, Italy
Novartis Investigative Site
Catanzaro, CZ, 88100, Italy
Novartis Investigative Site
Cona, FE, 44100, Italy
Novartis Investigative Site
Florence, FI, 50143, Italy
Novartis Investigative Site
Genova, GE, 16132, Italy
Novartis Investigative Site
Pozzilli, IS, 86077, Italy
Novartis Investigative Site
Lido di Camaiore, LU, 55041, Italy
Novartis Investigative Site
Monza, MB, 20900, Italy
Novartis Investigative Site
Milazzo, ME, 98057, Italy
Novartis Investigative Site
Milan, MI, 20122, Italy
Novartis Investigative Site
Modena, MO, 41100, Italy
Novartis Investigative Site
Piove di Sacco, PD, 35028, Italy
Novartis Investigative Site
Perugia, PG, 06100, Italy
Novartis Investigative Site
Pisa, PI, 56126, Italy
Novartis Investigative Site
Pescia, PT, 51017, Italy
Novartis Investigative Site
Casorate Primo, PV, 27022, Italy
Novartis Investigative Site
Pavia, PV, 27100, Italy
Novartis Investigative Site
Stradella, PV, 27049, Italy
Novartis Investigative Site
Albano Laziale, RM, 00041, Italy
Novartis Investigative Site
Roma, RM, 00163, Italy
Novartis Investigative Site
Battipaglia, SA, 84091, Italy
Novartis Investigative Site
Cava de' Tirreni, SA, 84013, Italy
Novartis Investigative Site
Salerno, SA, 84131, Italy
Novartis Investigative Site
Sassari, SS, 07100, Italy
Novartis Investigative Site
Thiesi, SS, 07047, Italy
Novartis Investigative Site
Palmanova, UD, 33057, Italy
Novartis Investigative Site
San Daniele del Friuli, UD, 33038, Italy
Novartis Investigative Site
Tradate, VA, 21049, Italy
Novartis Investigative Site
Varese, VA, 21100, Italy
Novartis Investigative Site
Vibo Valentia, VV, 89900, Italy
Novartis Investigative Site
Liepāja, LV, LV-3414, Latvia
Novartis Investigative Site
Daugavplis, LV-5417, Latvia
Novartis Investigative Site
Kuldīga, LV-3300, Latvia
Novartis Investigative Site
Preiļi, LV-5301, Latvia
Novartis Investigative Site
Riga, 1002, Latvia
Novartis Investigative Site
Ventspils, LV-3601, Latvia
Novartis Investigative Site
Kaunas, 50009, Lithuania
Novartis Investigative Site
Kaunas, LT-49387, Lithuania
Novartis Investigative Site
Kėdainiai, LT-57164, Lithuania
Novartis Investigative Site
Šiauliai, LT-76231, Lithuania
Novartis Investigative Site
Vilnius, LT-08661, Lithuania
Novartis Investigative Site
Pulau Pinang, Pulau Pinang, 10990, Malaysia
Novartis Investigative Site
Kuching, Sarawak, 94300, Malaysia
Novartis Investigative Site
Kuala Lumpur, 50400, Malaysia
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site
Aguascalientes, Aguascalientes, 20230, Mexico
Novartis Investigative Site
Guadalajara, Jalisco, 44280, Mexico
Novartis Investigative Site
Zapopan, Jalisco, 45200, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 03100, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 06700, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 06720, Mexico
Novartis Investigative Site
Mexico City, Mexico City, 07300, Mexico
Novartis Investigative Site
Monterrey, Nuevo León, 64710, Mexico
Novartis Investigative Site
Querétaro City, Querétaro, 76000, Mexico
Novartis Investigative Site
San Juan del Río, Querétaro, 76800, Mexico
Novartis Investigative Site
San Luis Potosí City, San Luis Potosí, 78200, Mexico
Novartis Investigative Site
San Luis Potosí City, San Luis Potosí, 78240, Mexico
Novartis Investigative Site
Ede, Netherlands, 6716 RP, Netherlands
Novartis Investigative Site
Eindhoven, Netherlands, 5623 EJ, Netherlands
Novartis Investigative Site
Hardenberg, Netherlands, 7770 AA, Netherlands
Novartis Investigative Site
Harderwijk, Netherlands, 3840 AC, Netherlands
Novartis Investigative Site
Oss, NL, 5342 BT, Netherlands
Novartis Investigative Site
's-Hertogenbosch, 5223 GZ, Netherlands
Novartis Investigative Site
Amersfoort, 3813 TZ, Netherlands
Novartis Investigative Site
Arnhem, 6815 AD, Netherlands
Novartis Investigative Site
Blaricum, 1261 AN, Netherlands
Novartis Investigative Site
Breda, 4818 CK, Netherlands
Novartis Investigative Site
Delft, 2625 AD, Netherlands
Novartis Investigative Site
Goes, 4462 RA, Netherlands
Novartis Investigative Site
Gorinchem, 4204 AA, Netherlands
Novartis Investigative Site
Heerenveen, 8441 PW, Netherlands
Novartis Investigative Site
Hengelo, 7555 DL, Netherlands
Novartis Investigative Site
Hoorn, 1625 HV, Netherlands
Novartis Investigative Site
Maastricht, 6229 HX, Netherlands
Novartis Investigative Site
Nijmegen, 6525 GA, Netherlands
Novartis Investigative Site
Sneek, 8601 ZK, Netherlands
Novartis Investigative Site
The Hague, 2512 VA, Netherlands
Novartis Investigative Site
Tilburg, 5022 GC, Netherlands
Novartis Investigative Site
Veldhoven, 5504 DB, Netherlands
Novartis Investigative Site
Panama City, Provincia de Panamá, 0831-02351, Panama
Novartis Investigative Site
Panama City, Provincia de Panamá, Panama
Novartis Investigative Site
Arequipa, Arequipa, Areq01, Peru
Novartis Investigative Site
Bellavista, Lima region, Callao 02, Peru
Novartis Investigative Site
Jesus Maria, Lima region, 11, Peru
Novartis Investigative Site
La Molina, Lima region, 12, Peru
Novartis Investigative Site
Lima Cercado, Lima region, 01, Peru
Novartis Investigative Site
San Borja, Lima region, 41, Peru
Novartis Investigative Site
San Isidro, Lima region, 27, Peru
Novartis Investigative Site
San Miguel, Lima region, 32, Peru
Novartis Investigative Site
Lipa City, Batangas, 4217, Philippines
Novartis Investigative Site
Quezon City, Manila, 1100, Philippines
Novartis Investigative Site
Quezon City, National Capital Region, 1109, Philippines
Novartis Investigative Site
Bulacan, Philippines, 3020, Philippines
Novartis Investigative Site
Manila, Philippines, 1000, Philippines
Novartis Investigative Site
Manila, Philippines, 1003, Philippines
Novartis Investigative Site
San Juan City, Philippines, 1500, Philippines
Novartis Investigative Site
Manila, Philippines
Novartis Investigative Site
Pasig, 1605, Philippines
Novartis Investigative Site
Quezon City, 1100, Philippines
Novartis Investigative Site
Quezon City, 1102, Philippines
Novartis Investigative Site
Bialystok, 15-875, Poland
Novartis Investigative Site
Gdynia, 81-157, Poland
Novartis Investigative Site
Gdynia, 81-472, Poland
Novartis Investigative Site
Gdynia, 81-519, Poland
Novartis Investigative Site
Gdynia, 81-548, Poland
Novartis Investigative Site
Gliwice, 44-100, Poland
Novartis Investigative Site
Golub-Dobrzyń, 87-400, Poland
Novartis Investigative Site
Katowice, 40-084, Poland
Novartis Investigative Site
Katowice, 40-530, Poland
Novartis Investigative Site
Katowice, 40-645, Poland
Novartis Investigative Site
Krakow, 30-015, Poland
Novartis Investigative Site
Krakow, 30-082, Poland
Novartis Investigative Site
Kutno, 99-300, Poland
Novartis Investigative Site
Lodz, 91-302, Poland
Novartis Investigative Site
Lublin, 20-857, Poland
Novartis Investigative Site
Oława, 55-200, Poland
Novartis Investigative Site
Skierniewice, 96-100, Poland
Novartis Investigative Site
Wroclaw, 50-088, Poland
Novartis Investigative Site
Wroclaw, 51-312, Poland
Novartis Investigative Site
Wroclaw, 52-612, Poland
Novartis Investigative Site
Zabrze, 41-800, Poland
Novartis Investigative Site
Porto, Porto District, 4200-319, Portugal
Novartis Investigative Site
Amadora, Portugal, 2720-276, Portugal
Novartis Investigative Site
Covilha, Portugal, 6200-251, Portugal
Novartis Investigative Site
Guimarães, Portugal, 4835-044, Portugal
Novartis Investigative Site
Lisbon, Portugal, 1169-024, Portugal
Novartis Investigative Site
Lisbon, Portugal, 1449-005, Portugal
Novartis Investigative Site
Penafiel, Portugal, 4564-007, Portugal
Novartis Investigative Site
Portalegre, Portugal, 7300-853, Portugal
Novartis Investigative Site
Vila Real, Portuigal, 5000-508, Portugal
Novartis Investigative Site
Setúbal, 2910-446, Portugal
Novartis Investigative Site
Bucharest, District 1, 014461, Romania
Novartis Investigative Site
Bucharest, District 1, Romania
Novartis Investigative Site
Bucharest, District 2, 021345, Romania
Novartis Investigative Site
Bucharest, District 5, 050538, Romania
Novartis Investigative Site
Craiova, Jud. Dolj, 200147, Romania
Novartis Investigative Site
Timișoara, Jud. Timis, 300359, Romania
Novartis Investigative Site
Craiova, Jud.Dolj, 200235, Romania
Novartis Investigative Site
Ploieşti, Jud.Prahova, 100410, Romania
Novartis Investigative Site
Arad, Romania, 310158, Romania
Novartis Investigative Site
Bucharest, Romania, 020054, Romania
Novartis Investigative Site
Bucharest, Romania, 050659, Romania
Novartis Investigative Site
Deva, Romania, 330084, Romania
Novartis Investigative Site
Timișoara, Romania, 300020, Romania
Novartis Investigative Site
Timișoara, Romania, 300041, Romania
Novartis Investigative Site
Timișoara, Romania, 300361, Romania
Novartis Investigative Site
Timișoara, Romania, 300736, Romania
Novartis Investigative Site
Bucharest, 011728, Romania
Novartis Investigative Site
Bucharest, 050098, Romania
Novartis Investigative Site
Bucharest, 060011, Romania
Novartis Investigative Site
Bucharest, 062272, Romania
Novartis Investigative Site
Piteşti, 110114, Romania
Novartis Investigative Site
Timișoara, 300310, Romania
Novartis Investigative Site
Gatchina, 188300, Russia
Novartis Investigative Site
Ivanovo, 153012, Russia
Novartis Investigative Site
Izhevsk, 426063, Russia
Novartis Investigative Site
Kazan', 420012, Russia
Novartis Investigative Site
Kemerovo, 650002, Russia
Novartis Investigative Site
Kemerovo, 650029, Russia
Novartis Investigative Site
Kemerovo, 650099, Russia
Novartis Investigative Site
Kirov, 610027, Russia
Novartis Investigative Site
Krasnodar, 350012, Russia
Novartis Investigative Site
Krasnodar, 350086, Russia
Novartis Investigative Site
Moscow, 101990, Russia
Novartis Investigative Site
Moscow, 105203, Russia
Novartis Investigative Site
Moscow, 105229, Russia
Novartis Investigative Site
Moscow, 109240, Russia
Novartis Investigative Site
Moscow, 111539, Russia
Novartis Investigative Site
Moscow, 115280, Russia
Novartis Investigative Site
Moscow, 115487, Russia
Novartis Investigative Site
Moscow, 115516, Russia
Novartis Investigative Site
Moscow, 117198, Russia
Novartis Investigative Site
Moscow, 117556, Russia
Novartis Investigative Site
Moscow, 119333, Russia
Novartis Investigative Site
Moscow, 119881, Russia
Novartis Investigative Site
Moscow, 119992, Russia
Novartis Investigative Site
Moscow, 121309, Russia
Novartis Investigative Site
Moscow, 121552, Russia
Novartis Investigative Site
Moscow, 125284, Russia
Novartis Investigative Site
Moscow, 127473, Russia
Novartis Investigative Site
N.Novgorod, 603005, Russia
Novartis Investigative Site
N.Novgorod, 603073, Russia
Novartis Investigative Site
Nizhny Novgorod, 603003, Russia
Novartis Investigative Site
Nizhny Novgorod, 603126, Russia
Novartis Investigative Site
Novosibirsk, 630051, Russia
Novartis Investigative Site
Novosibirsk, 630087, Russia
Novartis Investigative Site
Novosibirsk-117, 630117, Russia
Novartis Investigative Site
Orenburg, 460000, Russia
Novartis Investigative Site
Orenburg, 460040, Russia
Novartis Investigative Site
Penza, 440026, Russia
Novartis Investigative Site
Perm, 614097, Russia
Novartis Investigative Site
Petrozavodsk, 185019, Russia
Novartis Investigative Site
Rostov-on-Don, 344022, Russia
Novartis Investigative Site
S-Petersburg, 191144, Russia
Novartis Investigative Site
S.-Petersburg, 194354, Russia
Novartis Investigative Site
S.-Petersburg, 198205, Russia
Novartis Investigative Site
Saint Petersburg, 193163, Russia
Novartis Investigative Site
Saint Petersburg, 194017, Russia
Novartis Investigative Site
Saint Petersburg, 194044, Russia
Novartis Investigative Site
Saint Petersburg, 194295, Russia
Novartis Investigative Site
Saint Petersburg, 195067, Russia
Novartis Investigative Site
Saint Petersburg, 196084, Russia
Novartis Investigative Site
Saint Petersburg, 197022, Russia
Novartis Investigative Site
Saint Petersburg, 197119, Russia
Novartis Investigative Site
Saint Petersburg, 197341, Russia
Novartis Investigative Site
Saint Petersburg, 198013, Russia
Novartis Investigative Site
Saint Petersburg, 199106, Russia
Novartis Investigative Site
Samara, 443070, Russia
Novartis Investigative Site
Samara, 443095, Russia
Novartis Investigative Site
Saratov, 410012, Russia
Novartis Investigative Site
Saratov, 410028, Russia
Novartis Investigative Site
Smolensk, 214018, Russia
Novartis Investigative Site
St-Peterburg, 190000, Russia
Novartis Investigative Site
Syktyvkar, 167981, Russia
Novartis Investigative Site
Tula, 300053, Russia
Novartis Investigative Site
Tver', 170036, Russia
Novartis Investigative Site
Vladimir, 600020, Russia
Novartis Investigative Site
Volgograd, 400008, Russia
Novartis Investigative Site
Voronezh, 394065, Russia
Novartis Investigative Site
Yaroslavl, 150003, Russia
Novartis Investigative Site
Yaroslavl, 150062, Russia
Novartis Investigative Site
Yekaterinburg, 620028, Russia
Novartis Investigative Site
Yekaterinburg, 620102, Russia
Novartis Investigative Site
Yekaterinburg, 620137, Russia
Novartis Investigative Site
Singapore, Singapore, 119074, Singapore
Novartis Investigative Site
Singapore, Singapore, 169609, Singapore
Novartis Investigative Site
Singapore, Singapore, 308433, Singapore
Novartis Investigative Site
Singapore, Singapore, 768825, Singapore
Novartis Investigative Site
Bratislava, Slovak Republic, 841 04, Slovakia
Novartis Investigative Site
Brezno, Slovak Republic, 977 42, Slovakia
Novartis Investigative Site
Košice, Slovak Republic, 040 22, Slovakia
Novartis Investigative Site
Levice, Slovak Republic, 93401, Slovakia
Novartis Investigative Site
Prešov, Slovak Republic, 080 01, Slovakia
Novartis Investigative Site
Prešov, Slovak Republic, 08001, Slovakia
Novartis Investigative Site
Svidník, Slovak Republic, 08901, Slovakia
Novartis Investigative Site
Vranov nad Topľou, Slovak Republic, 09301, Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 821 07, Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 841 04, Slovakia
Novartis Investigative Site
Dunajská Streda, Slovakia, 929 01, Slovakia
Novartis Investigative Site
Košice, Slovakia, 040 01, Slovakia
Novartis Investigative Site
Košice, Slovakia, 04001, Slovakia
Novartis Investigative Site
Kráľovský Chlmec, Slovakia, 077 01, Slovakia
Novartis Investigative Site
Levice, Slovakia, 934 01, Slovakia
Novartis Investigative Site
Levice, Slovakia, 934 05, Slovakia
Novartis Investigative Site
Lučenec, Slovakia, 984 01, Slovakia
Novartis Investigative Site
Martin, Slovakia, 036 01, Slovakia
Novartis Investigative Site
Nitra, Slovakia, 949 88, Slovakia
Novartis Investigative Site
Trnava, Slovakia, 917 01, Slovakia
Novartis Investigative Site
Trnava, Slovakia, 91701, Slovakia
Novartis Investigative Site
Bratislava, 81369, Slovakia
Novartis Investigative Site
Bratislava, 851 07, Slovakia
Novartis Investigative Site
Dolný Kubín, 026 01, Slovakia
Novartis Investigative Site
Mthatha, Eastern Cape, South Africa
Novartis Investigative Site
Bloemfontein, Free State, 9301, South Africa
Novartis Investigative Site
Soweto, Gauteng, 2013, South Africa
Novartis Investigative Site
Middelburg, Mpumalanga, 1050, South Africa
Novartis Investigative Site
Paarl, Western Cape, 7626, South Africa
Novartis Investigative Site
Somerset West, Western Cape, 7130, South Africa
Novartis Investigative Site
Alberton, 1449, South Africa
Novartis Investigative Site
Bloemfontein, 9301, South Africa
Novartis Investigative Site
Bloemfontein, 9317, South Africa
Novartis Investigative Site
Breyten, 2330, South Africa
Novartis Investigative Site
Brits, 250, South Africa
Novartis Investigative Site
Cape Town, 7405, South Africa
Novartis Investigative Site
Cape Town, 7500, South Africa
Novartis Investigative Site
Cape Town, 7505, South Africa
Novartis Investigative Site
Cape Town, 7531, South Africa
Novartis Investigative Site
Cape Town, South Africa
Novartis Investigative Site
Durban, 4001, South Africa
Novartis Investigative Site
Durban, 4052, South Africa
Novartis Investigative Site
Durban, 4110, South Africa
Novartis Investigative Site
East London, South Africa
Novartis Investigative Site
eMkhomazi, 4170, South Africa
Novartis Investigative Site
Gatesville, 7764, South Africa
Novartis Investigative Site
Johannesburg, 2193, South Africa
Novartis Investigative Site
Kempton Park, 1620, South Africa
Novartis Investigative Site
Port Elizabeth, 6014, South Africa
Novartis Investigative Site
Pretoria, 0121, South Africa
Novartis Investigative Site
Pretoria, 0184, South Africa
Novartis Investigative Site
Pretoria, South Africa
Novartis Investigative Site
Witbank, South Africa
Novartis Investigative Site
Worcester, 6850, South Africa
Novartis Investigative Site
Busan, Busan, 602-739, South Korea
Novartis Investigative Site
Wŏnju, Gangwon-do, 220-701, South Korea
Novartis Investigative Site
Gwangju, Gwangju, 501-757, South Korea
Novartis Investigative Site
Suwon, Gyeonggi-do, 443-380, South Korea
Novartis Investigative Site
Seoul, Korea, 120-752, South Korea
Novartis Investigative Site
Seoul, Korea, 137-701, South Korea
Novartis Investigative Site
Seoul, Korea, 138-736, South Korea
Novartis Investigative Site
Daegu, 705-703, South Korea
Novartis Investigative Site
Daegu, 705-718, South Korea
Novartis Investigative Site
Pusan, 614-735, South Korea
Novartis Investigative Site
Seoul, 110-102, South Korea
Novartis Investigative Site
Seoul, 134-701, South Korea
Novartis Investigative Site
Seoul, 156-707, South Korea
Novartis Investigative Site
Almería, Andalusia, 04120, Spain
Novartis Investigative Site
Marbella, Andalusia, 29600, Spain
Novartis Investigative Site
Málaga, Andalusia, 29010, Spain
Novartis Investigative Site
Seville, Andalusia, 41014, Spain
Novartis Investigative Site
Seville, Andalusia, 41017, Spain
Novartis Investigative Site
Mallorca, Balearic Islands, 07198, Spain
Novartis Investigative Site
Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site
Sant Joan Despí, Catalonia, 08970, Spain
Novartis Investigative Site
Mérida, Extremadura, 06800, Spain
Novartis Investigative Site
A Coruña, Galicia, 15006, Spain
Novartis Investigative Site
Ferrol, Galicia, 15405, Spain
Novartis Investigative Site
Santiago de Compostela, Galicia, 15706, Spain
Novartis Investigative Site
Vigo, Galicia, 36211, Spain
Novartis Investigative Site
Alcalá de Henares, Madrid, 28805, Spain
Novartis Investigative Site
Madrid, Madrid, 28007, Spain
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site
Móstoles, Madrid, 28935, Spain
Novartis Investigative Site
El Palmar, Murcia, 30120, Spain
Novartis Investigative Site
Alicante, Valencia, 03004, Spain
Novartis Investigative Site
Valencia, Valencia, 46010, Spain
Novartis Investigative Site
Valencia, Valencia, 46015, Spain
Novartis Investigative Site
Gothenburg, 416 85, Sweden
Novartis Investigative Site
Gothenburg, Sweden
Novartis Investigative Site
Härnösand, 871 82, Sweden
Novartis Investigative Site
Helsingborg, 25232, Sweden
Novartis Investigative Site
Karlshamn, 37480, Sweden
Novartis Investigative Site
Lund, 221 85, Sweden
Novartis Investigative Site
Motala, 59185, Sweden
Novartis Investigative Site
Stockholm, 141 86, Sweden
Novartis Investigative Site
Vällingby, 162 68, Sweden
Novartis Investigative Site
Taichung, Taiwan, 40447, Taiwan
Novartis Investigative Site
Taipei, Taiwan, 10002, Taiwan
Novartis Investigative Site
Taipei, Taiwan, 114, Taiwan
Novartis Investigative Site
Tainan, Taiwan ROC, Taiwan
Novartis Investigative Site
Taipei, Taiwan, ROC, 112, Taiwan
Novartis Investigative Site
Changhua, 500, Taiwan
Novartis Investigative Site
Kaohsiung City, 82445, Taiwan
Novartis Investigative Site
Yilan, Taiwan
Novartis Investigative Site
Taladkwan, Changwat Nonthaburi, 11000, Thailand
Novartis Investigative Site
Muang, Muang, 65000, Thailand
Novartis Investigative Site
Muang, Thailand, 12120, Thailand
Novartis Investigative Site
Bangkok, 10400, Thailand
Novartis Investigative Site
Khon Kaen, 40002, Thailand
Novartis Investigative Site
Istanbul, Turkey, 34304, Turkey (Türkiye)
Novartis Investigative Site
Izmir, Turkey, 35040, Turkey (Türkiye)
Novartis Investigative Site
Adana, 01250, Turkey (Türkiye)
Novartis Investigative Site
Ankara, 06100, Turkey (Türkiye)
Novartis Investigative Site
Antalya, 07070, Turkey (Türkiye)
Novartis Investigative Site
Balcova / Izmir, 35340, Turkey (Türkiye)
Novartis Investigative Site
Edirne, 22030, Turkey (Türkiye)
Novartis Investigative Site
Etlik / Ankara, 06018, Turkey (Türkiye)
Novartis Investigative Site
Haseki / Istanbul, 34096, Turkey (Türkiye)
Novartis Investigative Site
Istanbul, 34093, Turkey (Türkiye)
Novartis Investigative Site
Kocaeli, 41380, Turkey (Türkiye)
Novartis Investigative Site
Mersin, 33079, Turkey (Türkiye)
Novartis Investigative Site
Meselik / Eskisehir, 26480, Turkey (Türkiye)
Novartis Investigative Site
Sivas, 58140, Turkey (Türkiye)
Novartis Investigative Site
Bristol, Bs2 8hw, United Kingdom
Novartis Investigative Site
Cambridge, Cambrigdeshire, CB2 0QQ, United Kingdom
Novartis Investigative Site
Durham, County Durham, DH1 5TW, United Kingdom
Novartis Investigative Site
Dorchester, Dorset, DT1 2JY, United Kingdom
Novartis Investigative Site
Brighton, East Sussex, BN2 5BE, United Kingdom
Novartis Investigative Site
Swansea, England, SA6 6NL, United Kingdom
Novartis Investigative Site
Romford, Essex, RM7 0AG, United Kingdom
Novartis Investigative Site
Basingstoke, Hampshire, RG24 9NA, United Kingdom
Novartis Investigative Site
Portsmouth, Hampshire, PO6 3LY, United Kingdom
Novartis Investigative Site
Royal Bridge Wells, Kent, TN4 8AT, United Kingdom
Novartis Investigative Site
Oldham, Lancashire, OL1 2JH, United Kingdom
Novartis Investigative Site
Leicester, Leicestershire, LE2 7LX, United Kingdom
Novartis Investigative Site
Craigavon, Northern Ireland, BT63 5QQ, United Kingdom
Novartis Investigative Site
Dundee, Perthshire, DD1 2BU, United Kingdom
Novartis Investigative Site
Taunton, Somerset, TA1 5DA, United Kingdom
Novartis Investigative Site
Yeovil, Somerset, BA21 4AT, United Kingdom
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
Novartis Investigative Site
Redhill, Surrey, RH1 5RH, United Kingdom
Novartis Investigative Site
South Shields, Tyne and Wear, NE34 0PL, United Kingdom
Novartis Investigative Site
Dudley, West Midlands, DY1 2HQ, United Kingdom
Novartis Investigative Site
Sutton Coldfield, West Midlands, B75 7RR, United Kingdom
Novartis Investigative Site
Birmingham, B18 7QH, United Kingdom
Novartis Investigative Site
Blackpool, FY3 8NR, United Kingdom
Novartis Investigative Site
Bournemouth, BH7 7DW, United Kingdom
Novartis Investigative Site
Bradford, BD9 6RJ, United Kingdom
Novartis Investigative Site
Cheshire, CW1 4QJ, United Kingdom
Novartis Investigative Site
Coventry, CV2 2DX, United Kingdom
Novartis Investigative Site
Croydon, CR7 7YE, United Kingdom
Novartis Investigative Site
Darlington, DL3 6HX, United Kingdom
Novartis Investigative Site
Exeter, EX2 5AX, United Kingdom
Novartis Investigative Site
Inverness, IV2 3UJ, United Kingdom
Novartis Investigative Site
Kent, DA2 8DA, United Kingdom
Novartis Investigative Site
Liverpool, L7 8XP, United Kingdom
Novartis Investigative Site
London, W1G 8PH, United Kingdom
Novartis Investigative Site
Londonderry, BT47 1SB, United Kingdom
Novartis Investigative Site
Manchester, M13 9WL, United Kingdom
Novartis Investigative Site
Middlesbrough, TS4 3BW, United Kingdom
Novartis Investigative Site
Milton Keynes, MK6 5LD, United Kingdom
Novartis Investigative Site
Newport, NP20 2UB, United Kingdom
Novartis Investigative Site
Newport, P030 5TG, United Kingdom
Novartis Investigative Site
Norwich, NR4 7UY, United Kingdom
Novartis Investigative Site
Poole, BH15 2JB, United Kingdom
Novartis Investigative Site
Rotherham, S60 2OD, United Kingdom
Novartis Investigative Site
Stevenage, SG1 4AB, United Kingdom
Novartis Investigative Site
Sunderland, SR4 7TP, United Kingdom
Novartis Investigative Site
Surrey, SM5 1AA, United Kingdom
Novartis Investigative Site
Vale of Glamorgan, CF64 2XX, United Kingdom
Novartis Investigative Site
Worcester, WR5 1DD, United Kingdom
Novartis Investigative Site
York, YO31 8HE, United Kingdom
Novartis Investigative Site
Caracas, Distrito Federal, 1060, Venezuela
Novartis Investigative Site
Caracas, Miranda, 1061, Venezuela
Novartis Investigative Site
Maturín, Monagas, 6201, Venezuela
Novartis Investigative Site
Maracaibo, Zulia, 4011, Venezuela
Novartis Investigative Site
Maracaibo, Zulia, Venezuela
Related Publications (52)
Yang M, Henderson AD, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Rouleau JL, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Rizkala A, Lewis EF, Jhund PS, Solomon SD, McMurray JJV. Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. Eur Heart J Cardiovasc Pharmacother. 2025 Nov 4;11(7):574-589. doi: 10.1093/ehjcvp/pvaf064.
PMID: 40839760DERIVEDChimura M, Butt JH, Matsumoto S, McMurray EGM, Henderson AD, Talebi A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, Jhund PS, McMurray JJV. Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HF. J Am Heart Assoc. 2025 May 6;14(9):e038249. doi: 10.1161/JAHA.124.038249. Epub 2025 Apr 23.
PMID: 40265590DERIVEDGupta SD, Butt JH, McMurray EGM, Talebi A, Matsumoto S, Rizkala AR, Henderson AD, Desai AS, Lefkowitz M, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, McMurray JJV; PARADIGM-HF Investigators and Committees. Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. Eur J Heart Fail. 2025 May;27(5):779-787. doi: 10.1002/ejhf.3515. Epub 2024 Nov 19.
PMID: 39563094DERIVEDLu H, Claggett BL, Packer M, Pfeffer MA, Swedberg K, Rouleau J, Zile MR, Lefkowitz M, Desai AS, Jhund PS, McMurray JJV, Solomon SD, Vaduganathan M. Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials. Eur J Heart Fail. 2025 Jan;27(1):60-68. doi: 10.1002/ejhf.3487. Epub 2024 Oct 22.
PMID: 39439294DERIVEDLu H, Claggett BL, Packer M, Lam CSP, Swedberg K, Rouleau J, Zile MR, Lefkowitz M, Desai AS, Jhund P, McMurray JJV, Solomon SD, Vaduganathan M. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. JAMA Cardiol. 2024 Nov 1;9(11):1047-1052. doi: 10.1001/jamacardio.2024.2566.
PMID: 39210725DERIVEDPatel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, Lefkowitz M, Gimpelewicz CR, Beste MT, Zhao F, Gou L, Desai AS, Jhund PS, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, Zannad F, Zile MR, McMurray JJV, Mendelson MM, Solomon SD, Cunningham JW. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy. J Am Heart Assoc. 2024 Jul 2;13(13):e033544. doi: 10.1161/JAHA.123.033544. Epub 2024 Jun 21.
PMID: 38904251DERIVEDChatur S, Neuen BL, Claggett BL, Beldhuis IE, Mc Causland FR, Desai AS, Rouleau JL, Zile MR, Lefkowitz MP, Packer M, McMurray JJV, Solomon SD, Vaduganathan M. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure. J Am Coll Cardiol. 2024 Jun 4;83(22):2148-2159. doi: 10.1016/j.jacc.2024.03.392. Epub 2024 Apr 6.
PMID: 38588927DERIVEDBhatt AS, Vaduganathan M, Claggett BL, Kulac IJ, Anand IS, Desai AS, Fang JC, Hernandez AF, Jhund PS, Kosiborod MN, Sabatine MS, Shah SJ, Vardeny O, McMurray JJV, Solomon SD, Gaziano TA. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials. J Am Heart Assoc. 2024 Mar 5;13(5):e032279. doi: 10.1161/JAHA.123.032279. Epub 2024 Feb 23.
PMID: 38390793DERIVEDCurtain JP, Adamson C, Docherty KF, Jhund PS, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan. JACC Heart Fail. 2023 Jul;11(7):749-759. doi: 10.1016/j.jchf.2022.12.012. Epub 2023 Apr 12.
PMID: 37407154DERIVEDKondo T, Dewan P, Anand IS, Desai AS, Packer M, Zile MR, Pfeffer MA, Solomon SD, Abraham WT, Shah SJ, Lam CSP, Jhund PS, McMurray JJV. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Circulation. 2023 Aug 29;148(9):732-749. doi: 10.1161/CIRCULATIONAHA.122.063642. Epub 2023 Jun 27.
PMID: 37366061DERIVEDTolomeo P, Butt JH, Kondo T, Campo G, Desai AS, Jhund PS, Kober L, Lefkowitz MP, Rouleau JL, Solomon SD, Swedberg K, Vaduganathan M, Zile MR, Packer M, McMurray JJV. Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. Eur Heart J. 2023 Jun 25;44(24):2202-2212. doi: 10.1093/eurheartj/ehad210.
PMID: 37051752DERIVEDButt JH, Ibrahim W, Dewan P, Desai AS, Kober L, Prescott MF, Lefkowitz MP, Rouleau JL, Solomon SD, Zile MR, Packer M, Jhund PS, McMurray JJV. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 Mar;16(3):e010111. doi: 10.1161/CIRCHEARTFAILURE.122.010111. Epub 2023 Jan 25.
PMID: 36943907DERIVEDRohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2023 Feb 1;8(2):150-158. doi: 10.1001/jamacardio.2022.4427.
PMID: 36477809DERIVEDVaduganathan M, Claggett BL, McMurray JJV, Solomon SD. Health Status Trajectories Before and After Hospitalization for Heart Failure. Circulation. 2022 Jun 21;145(25):1872-1874. doi: 10.1161/CIRCULATIONAHA.122.059282. Epub 2022 May 21. No abstract available.
PMID: 35603665DERIVEDToenges G, Mutze T, Jahn-Eimermacher A. A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials. Stat Med. 2021 Nov 20;40(26):5702-5724. doi: 10.1002/sim.9149. Epub 2021 Jul 30.
PMID: 34327735DERIVEDShen L, Claggett BL, Jhund PS, Abraham WT, Desai AS, Dickstein K, Gong J, Kober LV, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, McMurray JJV. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug;110(8):1334-1349. doi: 10.1007/s00392-021-01888-x. Epub 2021 Jun 8.
PMID: 34101002DERIVEDShen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, Martinez FA, Pfeffer MA, Rizkala AR, Rouleau JL, Swedberg K, Vaduganathan M, Vardeny O, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 Apr 27;77(16):1961-1973. doi: 10.1016/j.jacc.2021.03.001.
PMID: 33888245DERIVEDEhteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 Feb 16;10(4):e019238. doi: 10.1161/JAHA.120.019238. Epub 2021 Jan 30.
PMID: 33522249DERIVEDKristensen SL, Castagno D, Shen L, Jhund PS, Docherty KF, Rorth R, Abraham WT, Desai AS, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail. 2020 Dec;22(12):2370-2379. doi: 10.1002/ejhf.1972. Epub 2020 Sep 14.
PMID: 32720404DERIVEDDocherty KF, Shen L, Castagno D, Petrie MC, Abraham WT, Bohm M, Desai AS, Dickstein K, Kober LV, Packer M, Rouleau JL, Solomon SD, Swedberg K, Vazir A, Zile MR, Jhund PS, McMurray JJV. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):528-538. doi: 10.1002/ejhf.1682. Epub 2019 Dec 17.
PMID: 31849164DERIVEDDewan P, Rorth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Kober L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9.
PMID: 31813280DERIVEDSolomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17.
PMID: 31736342DERIVEDSelvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 Oct 22;140(17):1369-1379. doi: 10.1161/CIRCULATIONAHA.119.039920. Epub 2019 Sep 12.
PMID: 31510768DERIVEDChandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.
PMID: 31302043DERIVEDBalmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 Jun;7(6):457-465. doi: 10.1016/j.jchf.2019.02.015. Epub 2019 May 8.
PMID: 31078482DERIVEDMyhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018. Epub 2019 Mar 4.
PMID: 30846338DERIVEDZile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. J Am Coll Cardiol. 2019 Feb 26;73(7):795-806. doi: 10.1016/j.jacc.2018.11.042.
PMID: 30784673DERIVEDBouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 Dec;20(12):1701-1709. doi: 10.1002/ejhf.1301. Epub 2018 Sep 11.
PMID: 30204280DERIVEDO'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 May;11(5):e004446. doi: 10.1161/CIRCHEARTFAILURE.117.004446.
PMID: 29748349DERIVEDPacker M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554. doi: 10.1016/S2213-8587(18)30100-1. Epub 2018 Apr 13.
PMID: 29661699DERIVEDChandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 Jun 1;3(6):498-505. doi: 10.1001/jamacardio.2018.0398.
PMID: 29617523DERIVEDShen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, Abraham WT, Dickstein K, Kober L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov;10(11):e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.
PMID: 29141857DERIVEDKristensen SL, Jhund PS, Mogensen UM, Rorth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Kober L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct;10(10):e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.
PMID: 29018174DERIVEDLewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug;10(8):e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430.
PMID: 28784687DERIVEDZile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436. doi: 10.1016/j.jacc.2016.09.931.
PMID: 27908347DERIVEDNadruz W Jr, Claggett BL, McMurray JJ, Packer M, Zile MR, Rouleau JL, Desai AS, Swedberg K, Lefkowitz M, Shi VC, Prescott MF, Solomon SD. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 Nov 29;134(22):1785-1787. doi: 10.1161/CIRCULATIONAHA.116.024976. No abstract available.
PMID: 27895026DERIVEDDesai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733.
PMID: 27842179DERIVEDOkumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016 Sep;9(9):e003212. doi: 10.1161/CIRCHEARTFAILURE.116.003212.
PMID: 27618854DERIVEDSolomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Oct;4(10):816-822. doi: 10.1016/j.jchf.2016.05.002. Epub 2016 Jul 6.
PMID: 27395349DERIVEDKristensen SL, Martinez F, Jhund PS, Arango JL, Belohlavek J, Boytsov S, Cabrera W, Gomez E, Hagege AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016 Nov 1;37(41):3167-3174. doi: 10.1093/eurheartj/ehw226. Epub 2016 Jun 28.
PMID: 27354044DERIVEDDesai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 Jun;9(6):e002735. doi: 10.1161/CIRCHEARTFAILURE.115.002735.
PMID: 27296397DERIVEDOkumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees*. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 7;133(23):2254-62. doi: 10.1161/CIRCULATIONAHA.115.020729. Epub 2016 Apr 20.
PMID: 27143684DERIVEDSolomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
PMID: 26915374DERIVEDKristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan;9(1):e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.
PMID: 26754626DERIVEDSimpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071. doi: 10.1016/j.jacc.2015.08.878.
PMID: 26541915DERIVEDAndersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):14-22. doi: 10.1111/bcpt.12453. Epub 2015 Sep 4.
PMID: 26280447DERIVEDJhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015 Oct 7;36(38):2576-84. doi: 10.1093/eurheartj/ehv330. Epub 2015 Jul 31.
PMID: 26231885DERIVEDDesai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 7;36(30):1990-7. doi: 10.1093/eurheartj/ehv186. Epub 2015 May 28.
PMID: 26022006DERIVEDMcMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Belohlavek J, Bohm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R; PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14;36(7):434-9. doi: 10.1093/eurheartj/ehu455.
PMID: 25416329DERIVEDPacker M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlavek J, Bohm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzalez-Medina A, Hagege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan O, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.
PMID: 25403646DERIVEDMcMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
PMID: 25176015DERIVEDMcMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.
PMID: 23563576DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Study Director
- Organization
- Novartis Pharmaceuticals
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 16, 2009
First Posted
December 18, 2009
Study Start
December 1, 2009
Primary Completion
May 1, 2014
Study Completion
May 1, 2014
Last Updated
August 15, 2016
Results First Posted
September 7, 2015
Record last verified: 2016-07